Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders - PubMed

Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders

Alessandro Serretti et al. Psychiatry Res. 2007.

Abstract

The short variant of the serotonin transporter gene (SERTPR) has been consistently associated with a poorer response to treatment with various selective serotonin reuptake inhibitors (SSRIs). Antidepressant response is not a unitary phenomenon, however, and we here hypothesized that the SERTPR effect could be specific to some types of symptomatology. The sample comprised 281 inpatients affected by mood disorders and treated for major depression with SSRIs. The total depressive scores for all patients were analyzed in previous reports, but symptomatologic clusters were not examined previously. The 21-item Hamilton Rating Scale for Depression (HAM-D) was administered to evaluate depressive symptoms at baseline and weekly over 6 weeks of treatment. All patients were genotyped for the SERTPR polymorphism. Compared with patients with the SERTPR l/l and l/s polymorphisms, s/s patients showed a selective and slower improvement of depressive "core" and somatic anxiety symptoms, but they did not differ from other patients regarding other symptomatologic clusters such as insomnia and motor retardation. These findings support the view that response to SSRIs is not a unitary phenomenon and that improvement of symptomatologic clusters as, at least in part, genetically driven. SERTPR may be hypothesized as concurrently participating to the activity of anatomic brain regions differentially involved in depression and somatic symptoms of anxiety; however, further studies are required to examine these complex interactions.

Similar articles

• Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.

  Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Serretti A, et al. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):36-40. doi: 10.1002/ajmg.b.30027. Am J Med Genet B Neuropsychiatr Genet. 2004. PMID: 15274037 Clinical Trial.

• 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.

  Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A. Kato M, et al. Psychiatry Res. 2009 May 15;167(1-2):97-105. doi: 10.1016/j.psychres.2007.12.012. Epub 2009 Apr 10. Psychiatry Res. 2009. PMID: 19361869

• The serotonin transporter gene and effectiveness of SSRIs.

  Serretti A, Kato M. Serretti A, et al. Expert Rev Neurother. 2008 Jan;8(1):111-20. doi: 10.1586/14737175.8.1.111. Expert Rev Neurother. 2008. PMID: 18088204 Review.

• Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis.

  Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E. Serretti A, et al. Psychiatry Res. 2006 Nov 29;145(1):61-5. doi: 10.1016/j.psychres.2005.09.020. Epub 2006 Oct 27. Psychiatry Res. 2006. PMID: 17069894

• Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

  Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Smits KM, et al. Mol Psychiatry. 2004 May;9(5):433-41. doi: 10.1038/sj.mp.4001488. Mol Psychiatry. 2004. PMID: 15037864 Review.

Cited by

• Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.

  Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC, Aitchison KJ, Pariante CM. Su KP, et al. Biol Psychiatry. 2010 Mar 15;67(6):550-7. doi: 10.1016/j.biopsych.2009.11.005. Epub 2009 Dec 24. Biol Psychiatry. 2010. PMID: 20034614 Free PMC article.

• Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice.

  Rundell JR, Harmandayan M, Staab JP. Rundell JR, et al. Transl Psychiatry. 2011 May 10;1(5):e6. doi: 10.1038/tp.2011.7. Transl Psychiatry. 2011. PMID: 22832401 Free PMC article.

• Distinctive Clinical Correlates of Psychotic Major Depression: The CRESCEND Study.

  Park SC, Lee HY, Sakong JK, Jun TY, Lee MS, Kim JM, Kim JB, Yim HW, Park YC. Park SC, et al. Psychiatry Investig. 2014 Jul;11(3):281-9. doi: 10.4306/pi.2014.11.3.281. Epub 2014 Jul 21. Psychiatry Investig. 2014. PMID: 25110501 Free PMC article.

• Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.

  Manoharan A, Shewade DG, Rajkumar RP, Adithan S. Manoharan A, et al. Eur J Clin Pharmacol. 2016 Oct;72(10):1215-1220. doi: 10.1007/s00228-016-2099-9. Epub 2016 Jul 20. Eur J Clin Pharmacol. 2016. PMID: 27439447

• Serotonin transporter polymorphism is associated with increased apnea-hypopnea index in older adults.

  Schröder CM, Primeau MM, Hallmayer JF, Lazzeroni LC, Hubbard JT, O'Hara R. Schröder CM, et al. Int J Geriatr Psychiatry. 2014 Mar;29(3):227-35. doi: 10.1002/gps.3994. Epub 2013 Jun 11. Int J Geriatr Psychiatry. 2014. PMID: 23754303 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information